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Immune gene therapyAbstract The annual incidence of thyroid cancer worldwide is alarming. Despite current various
treatments such as surgical resection, radioiodine therapy and chemotherapy/radiotherapy, thyroid
carcinoma remains a lethal cancer. Assuredly, the operative and new treatment strategies are nec-
essary to control this malignancy. Gene therapy is regarded as one of the most reliable novel ther-
apeutic methods for hopeless cases of thyroid cancer and those who do not respond to the prevalent
treatments. Accumulated evidence suggests that interleukin-24 (IL-24), also known as melanoma
differentiation-associated gene-7, has very important roles in regulation of cell differentiation, cell
growth and apoptosis, and it is also a promising anticancer agent. Here, we propose that it could be
advantageous to evaluate the anti-tumoural effect of IL-24 in a mouse xenograft model of thyroid
cancer.
ª 2013 Tehran University of Medical Sciences. Published by Elsevier Ltd.
D license.Introduction
The thyroid is a main human endocrine gland that controls
heart rate, blood pressure, body temperature and metabolism[1]. Thyroid carcinoma is the most frequent endocrine malig-
nancy [2], and its incidence is more common than ovarian, uri-
nary bladder or pancreatic cancer, with an incidence 3 times
higher in women than in men [3].e-linked
damage;
98 241
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thyroid cancer have few therapeutic options, with a 30% re-
sponse rate to systemic chemotherapy and no proven survival
beneﬁt [4].
Papillary thyroid cancer (PTC) is the most common histo-
logical type of thyroid malignancy [5]. The genetic malfunc-
tions that cause thyroid neoplasia include rearrangements
and point mutations in some genes, such as RAS, RET and
p53. Specially, deﬁciency in DNA repair, apoptosis and tu-
mour suppressor gene malfunction result in thyroid tumours
[5].
Despite many traditional treatments for thyroid cancer,
including surgical resection, radioiodine therapy, thyrotropin
(thyroid stimulating hormone, TSH)-suppressive thyroxine
treatment and chemotherapy/radiotherapy, the chance of sur-
vival in patients is low. Thus, alternative approaches, such as
gene therapy, are of interest, and fortunately, thyroid tumours
are a good target, for two reasons. First, certain gene promot-
ers expressed in the thyroid tumours have no or very limited
expression elsewhere, and second, if the therapy leads to
destruction of all normal thyroid tissue, this would be inconse-
quential to destruction of the other tissues [5,6]. Gene therapy
can be effective and safe, but for each approach there is an
evaluation between the degree of effectiveness and undesirable
toxic effects that may occur due to non-selectivity. For exam-
ple, Nishihara et al. have reported the effect of Re-TG-tk/Cre-
loxP on FRTL-5, FRTC and FRO cell lines, which has extra-
thyroidal tissue toxicity. In addition, Zang et al. had shown an
anti-tumoural effect of Ad–TG-tk and Ad–CMV-tk in FRTL-
5, HEPG2, COS-1, MTC, HeLa and GH3 cells which were not
effective in the anaplastic form besides severe liver damage.
Barzon et al. have evaluated Re-tk-IL-2 in human ATC cell
line. This strategy had low efﬁciency in addition to the mild
side effects. Adenoviruses and other viruses have been engi-
neered for selective replication within neoplastic cells. It is al-
most impossible to deliver the virus to all the tumoural cells;
therefore, the uninfected tumoural cells will continue to
grow [7].
In this hypothesis, we focussed on the tumour suppressive
function of melanoma differentiation associated gene-7/inter-
leukin-24 (MDA-7/IL-24) in a xenograft mouse model for thy-
roid carcinoma. Based on the sequence homology, FISP is the
mouse orthologue of mda-7/IL-24 [8]. MDA-7, also known as
IL-24, is a member of the class II/IL-10 cytokine family [9,10]
and has been mapped to 1q32.2-q41 [11,12]. MDA-7 is ex-
pressed by the spleen, thymus and immune cells, including
TH2 cells, B cells, natural killer (NK) cells, dendritic cells,
monocytes and melanocytes [13–15]. Further, MDA-7 is
expressed in the villi, decidual tissue, villous column, tropho-
blasts, stroma and blood vessels [16]. The IL-20R1:IL-20R2
complex is a heterodimer receptor for IL-24. The latter also
signals through an IL-22R1/IL-20R2 heterodimer (type II
complex) [10,17–23]. Generally, epithelial cells are major
expression sites for IL-24 receptors [24]. A high level of IL-
20R1 messenger RNA (mRNA) expression was indicated in
the skin, testis, heart, placenta, salivary gland and prostate.
Mild expression was detected in brain, lung, stomach, pan-
creas, ovary, uterus, thyroid and adrenal glands. Scarce expres-
sion was observed in the kidney, liver, colon, muscle and smallintestine [25]. Mda-7 has at least two separate functions. It
mostly acts as a cytokine at low concentration. However, over-
expression of IL-24 at the supra-physiological level shows an
irreversible cancer cell growth inhibitory function and G2/M
cell cycle arrest, reversal of the malignant phenotype and ter-
minal differentiation, without negative effects on normal cells
[26,27]. When IL-24 as a cytokine binds to its receptor, Janus
activating kinase 1 (JAK1) is activated and causes the receptor
phosphorylation and creates binding sites for signal transduc-
ers and activators of transcription 1 (STAT1) and STAT3,
which are also phosphorylated by JAK1. The phosphorylated
STATs, in the nucleus, promote the transcription of cytokine-
regulated genes. This is the ﬁrst function of mda-7 [28,29].
However, it does not depend on this pathway to induce apop-
tosis [24]. Recombinant (r)IL-24 stimulates genes of the extrin-
sic and intrinsic apoptotic pathway such as Bax, Bak, Bid,
Casp8, cytochrome c oxidase subunit VIc (COX6C) and cyto-
chrome c oxidase subunit VIIb (COX7B) [30]. In fact, IL-24-
induced apoptosis is conducted through down-regulation of
Bcl-2, Bax and Akt [13]. However, Mda-7 induces the secretion
of interferon-beta (IFN-beta), which subsequently leads to
interferon regulatory factor (IRF-1) regulation and Fas/tu-
mour necrosis factor-related apoptosis-inducing ligand (Fas/
TRAIL) activation. Furthermore, MDA-7 has been implicated
in inducing cell death with the contribution of ceramide, a pro-
moter of apoptosis and a key mediator of the endoplasmic
reticulum (ER) stress pathway [31]. Mda-7/IL-24 binding to
BiP/GRP78 inactivates this ER-chaperone protein by in-
creased protein kinase RNA-activated (PKR)-like endoplas-
mic reticulum kinase (PERK) autophosphorylation and
increased phosphorylation of the downstream PERK target
(eukaryotic initiation factor 2, eIF2) [32,33] and therefore
could lead to a general suppression of protein expression,
particularly of anti-apoptotic proteins, such as Bcl2, Bcl-XL,
induced myeloid leukaemia cell differentiation protein
(MCL-1) and cellular FLICE-like inhibitory protein (c-FLIP)
[31] Mda-7/IL-24 induced ER stress and ceramide accumula-
tion, which triggered autophagy.
Producers of reactive oxygen species (ROS) enhance MDA-
7/IL-24 lethality. Overexpression of MDA-7/IL-24 in renal cell
carcinoma caused plasma membrane clustering of CD95 and
CD95 association with pro-caspase 8, which correlated with
enhanced cell killing [34]. IL-24 also has immune stimulatory
activity. It activates IL-6, tumour necrosis factor-a
(TNF-a) and interferon production and has been shown to
signiﬁcantly down-regulate transforming growth factor-b
(TGF-b) [35–37].The hypothesis
Thyroid cancer is the sixth most common type of cancer
among women and it is increasing more rapidly than any other
cancer. Therefore, development and evaluation of novel treat-
ment strategies, including immune gene therapy, are urgently
needed. In this proposal, we suggest inducing IL-24 gene
expression in the HTori human thyroid cell line and injection
of this cell line into a xenograft system. In the last years, IL-
24 has been introduced as a novel tumour suppressor gene
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is even applied in patients with some types of malignancies. We
expect that IL-24 can enhance malignant cell death through
apoptosis and other possible pathways in a thyroid mouse
model without any effect in normal cells.
Evaluation of hypothesis
 Cell culture: The human thyroid epithelial cell line (HTori-
3) is grown in phenol red-free RPMI 1640, supplemented
with 1% (v/v) antibiotics/antimycotics, 2 mmol/L of L-glu-
tamine and 10% (v/v) foetal calf serum (FCS) [38].
 Construction of recombinant adenovirus: The IL-24 expres-
sion cassette is cloned into the adenovirus shuttle plasmid
pCA13 to form pCA13–IL-24 and cut with BglII to clone
into ZD55 to form pZD55–IL-24. Replication-defective
adenovirus Ad–IL-24 is generated in HTori cells by homol-
ogous recombination. Recombinant adenovirus is ampliﬁed
in HTori cells and puriﬁed by caesium chloride-gradient
ultracentrifugation [34].
Brieﬂy, recombinant adenovirus plasmid pAd–mda-7 carry-
ing human mda-7/IL-24 complementary DNA (cDNA) is
transfected into the human thyroid epithelial cell line (HTor-
i-3) by Lipofectamine 2000 reagent, leading to the formation
of the recombinant adenovirus, Ad–IL-24. At the same time,
the recombinant adenovirus Ad-GFP carrying green ﬂuores-
cent protein (GFP) is constructed as a control.
 Tumour xenograft in nude mice: A total of 40 athymic mice
(AthymicNCr-nu/nu; 4 weeks old) are prepared. The ﬁrst
group (n= 10) contains control animals, which do not
receive any injection. The remaining mice are divided into
three categories of 10 animals each, including the following:
(a) Ten mice are selected for HTori cell-line inoculation. HTori
cells (5 · 106) in 200 ll of suspension mixture are injected
subcutaneously (s.c.) into the right ﬂank of athymic mice.
Tumours are measured weekly and the ‘end’ point was
reached when the tumours reached 3 cm in diameter [38].
(b) The second group received HTori cells and empty ade-
novirus vector.
(c) The next group includes mice that are injected with
HTori cells according to the above instruction. This
group received Ad–IL-24 (Fig. 1).
 RNA isolation and reverse transcriptase-polymerase chain
reaction (RT-PCR): RNA from cells is extracted using an
RNA extraction kit and cDNA synthesis and RT-PCR
are performed.
 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay: The cytotoxic activity of Ad–IL-24 is deter-
mined based on cytotoxicity to HTori cells, using the MTT
assay.
 Enzyme-linked Immunosorbent Assay (ELISA): ELISA is
performed to measure level of IL-24 in blood.
 Terminal deoxynucleotidyl transferase deoxy-uridinetri-
phosphate (dUTP) nick end labelling (TUNEL) test: This
test is used to assay DNA fragmentation, as a marker of
apoptosis [39,40]. Evaluating IFN-gamma, Granzyme B, TNF-alpha and IL-
24 through ELISA assay.
Discussion and conclusion
Given the lack of a promising cure for thyroid malignancy,
cytokine gene therapy for cancer has been recognised as an
efﬁcient and novel treatment with the minimum side effects
[5,6]. Among cytokines, mda-7/IL-24 as a new tumour sup-
pressor gene has been investigated in animal models and
in vitro studies [26,27]. Many studies show cytotoxic effects
of IL-24 in various types of cancer cell lines, including glioma,
ovarian, breast, lung, liver, pancreatic, gastric, colorectal, renal
and prostate cancer cells [41,42]. In addition, overexpression of
mda-7 in cervical cancer, ﬁbrosarcoma, melanoma, hepatoma
and osteosarcoma cell lines led to programmed cell death. Fur-
thermore, the anti-tumour activity of IL-24 has been estab-
lished in some tumour xenograft models and even in patients
with advanced solid cancers [13,14,28,43]. MDA-7 also inﬂu-
ences endothelial cells and has an anti-angiogenic effect within
the tumour vasculature [13,9]. A Phase I/II clinical trial in pa-
tients with advanced carcinomas involving intratumoural
administration of mda-7/IL-24 has documented that this gene
is safe and well tolerated by patients and a single virus injec-
tion elicits apoptosis in a majority of the tumours [44,45].
cDNA libraries produced from H0-1 cells treated with
IFN-beta + mezerein (MEZ) led to identiﬁcation of this gene
[46,47].
Our hypothesis suggested that Ad–IL-24 can inhibit the
growth and proliferation of human epithelial thyroid HTori
cells in tumour-bearing mice. IL-24 is a regulator of cell differ-
entiation, cell growth and apoptosis and a promising antican-
cer agent in many types of tumour cell lines without toxic
effects in ‘normal’ cell types [40,48]. This cytokine can induce
both intrinsic and extrinsic apoptosis pathways. In the extrin-
sic pathway, IL-24 efﬁciently could suppress tumours through
TNF-a and activation of the caspase 8–caspase 3 [48]; in the
intrinsic pathway, induction of caspase 9 and bax gene expres-
sion were observed [37]. In ovarian cancer, mda-7/IL24 was re-
ported to induce the extrinsic apoptosis pathway and also kill
multiple renal carcinoma cell lines, also via activation of the
CD95/FAS receptor [32]. IL-24-induced inhibition of cell pro-
liferation was associated with the transcriptional up-regulation
of the cell cycle inhibitors mediated by STAT3 activation
[49,50]. Another study demonstrated the potential anti-tumour
activity of IFN-a combined with IL-24 in hepatocellular carci-
noma (HCC) both in vitro and in vivo [51]. Interestingly, stud-
ies have shown that one mechanism of clinically effective IL-2
therapy may be the direct action of IL-2 on up-regulation of
the tumour suppressor IL-24 [52]. Mda-7/IL-24 also can en-
hance tumour sensitivity to radiation therapy [53,54]. Recent
studies have demonstrated that IL-24 can regulate ER stress
following the binding of the protein to BiP/GRP78. This bind-
ing eventually leads to the phosphorylation of eIF2 and there-
fore to a general suppression of anti-apoptotic proteins, such
as Bcl-XL, MCL-1 and c-FLIP [31]. Further in vivo data
showed that IL-24 suppressed tumour growth through
up-regulating the expression of bax and down-regulating the
Figure 1 IL-24 as an anticancer cytokine in gene therapy of thyroid carcinoma schematic design of hypothesis procedure. Function of
IL-24 in different cells.
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(VEGF) [28,29,49,55,56].
Moreover, IL-24 induces cancer cell-speciﬁc oxidative stress
by generation of ROS followed by mitochondrial dysfunction
uniquely in cancer cells [43]. Therefore, the canonical mecha-
nism by which diverse cytokines, including members of the
IL-10 gene family, are proposed to mediate bioactivity is by
binding to deﬁned cell surface receptors and activating JAK/
STAT signalling pathways. In the case of mda-7/IL-24,
JAK1/STAT3 activation is induced after binding of the
Mda-7/IL-24 protein to the IL-20R1/IL-20R2 and IL-22R1/
IL-20R2 receptors. Meanwhile, cell killing by mda-7/IL-24
did not require functional cell-surface receptors or STATactivation, and inhibition of tyrosine kinase activity or infec-
tion of cancer cells defective in speciﬁc components of the
JAK/STAT signalling pathway still elicited apoptosis [37,55].
However, Mda-7 expression is substantially reduced in malig-
nant breast tissue and low transcript levels are signiﬁcantly
associated with unfavourable pathological parameters.
Mda-7 probably offers utility as a prognostic marker in
thyroid carcinoma [13].
In conclusion, cytokine gene therapy demonstrates safety
and effectiveness in thyroid carcinoma. Specially, IL-24 could
act as an effective anticancer agent in this cancer via inducing
apoptosis, according to recent documents on many other types
of cancer.
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about the subject?
Thyroid cancer incidence is increasing
more rapidly than any other malignancy.
The expected annual number of newly
diagnosed thyroid cancer cases in the US
has reached 37,340. Despite current treat-
ments for thyroid cancer, other efﬁcient
approaches are necessary. It is veriﬁed that
IL-24 has tumour suppressor function
through inducing both intrinsic and extrin-
sic apoptosis pathways. Interestingly, simi-
lar effects are not apparent following
transduction into their non-malignant
counterparts. IL-24 can suppress cancer cell
growth, induce cancer cell apoptosis, inhibit
angiogenesis and enhance the anti-tumour
activity of radiotherapy, chemotherapy
and targeting gene-virotherapy.
Second Question: What does your proposed
theory add to the current knowledge avail-
able, and what beneﬁts does it have?
IL-24 could be considered a novel candi-
date in the gene therapy of thyroid cancer.
It could suppress the thyroid tumoural cell
growth and angiogenesis conspicuously
through up-regulating the expression of
pro-apoptotic proteins (bax and Bak) and
down-regulating the expression of bcl-2,
Bcl-xL and VEGF, promoting a shift from
survival to programmed cell death.
Third question: Among numerous available
studies, what special further study is proposed
for testing the idea?
To test this idea, initially epithelial thyroid
tumoural cells are induced in a mouse model
via an adenovirus vector. Then, the anti-
tumoural effect of IL-24 could be assessed
by methods of measurement of biomarkers
in blood levels.
In last phase, a clinical trial could be
performed.Acknowledgement
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